Jagsonpal Pharmaceuticals credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−106−106−129−148−115
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.38×−0.38×−0.54×−0.79×−0.72×
−1.73×−1.83×−2.52×−6.41×−3.36×
47.31×47.31×44.82×26.29×79.83×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JAGSNPHARM₹211.35

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,415 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Net Debt-114.6-147.9-128.7-106.1-106.1
Net Debt/Equity-0.72-0.79-0.54-0.38-0.38
Net Debt/EBITDA-3.36-6.41-2.52-1.83-1.73
Interest Coverage (EBIT/Interest)79.8326.2944.8247.3147.31
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.